These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25299637)

  • 1. Sugammadex: A Scientific Review Including Safety and Efficacy, Update on Regulatory Issues, and Clinical Use in Europe.
    Jahr JS; Miller JE; Hiruma J; Emaus K; You M; Meistelman C
    Am J Ther; 2015; 22(4):288-97. PubMed ID: 25299637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugammadex: A Comprehensive Review of the Published Human Science, Including Renal Studies.
    Partownavid P; Romito BT; Ching W; Berry AA; Barkulis CT; Nguyen KP; Jahr JS
    Am J Ther; 2015; 22(4):298-317. PubMed ID: 25299638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion.
    Haerter F; Eikermann M
    Expert Opin Pharmacother; 2016; 17(6):819-33. PubMed ID: 26799963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions.
    Akha AS; Rosa J; Jahr JS; Li A; Kiai K
    Anesthesiol Clin; 2010 Dec; 28(4):691-708. PubMed ID: 21074746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drug sugammadex: a selective relaxant binding agent.
    Welliver M
    AANA J; 2006 Oct; 74(5):357-63. PubMed ID: 17048555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sugammadex: a selective relaxant-binding agent providing rapid reversal.
    Rex C; Bergner UA; Pühringer FK
    Curr Opin Anaesthesiol; 2010 Aug; 23(4):461-5. PubMed ID: 20489603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do we need to use sugammadex at the end of a general anesthesia to reverse the action of neuromuscular bloking agents? Position Paper on Sugammadex use.
    Della Rocca G; Di Marco P; Beretta L; De Gaudio AR; Ori C; Mastronardi P
    Minerva Anestesiol; 2013 Jun; 79(6):661-6. PubMed ID: 23192221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugammadex in anesthesia practice.
    Duvaldestin P; Plaud B
    Expert Opin Pharmacother; 2010 Nov; 11(16):2759-71. PubMed ID: 20977408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
    Hogg RM; Mirakhur RK
    Expert Rev Neurother; 2009 May; 9(5):599-608. PubMed ID: 19402771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of sugammadex.
    Bom A; Hope F; Rutherford S; Thomson K
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sugammadex: a new approach to muscle relaxation and its reversal].
    Duvaldestin P
    Ann Fr Anesth Reanim; 2009 Sep; 28 Suppl 2():S39-40. PubMed ID: 19887275
    [No Abstract]   [Full Text] [Related]  

  • 16. Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Nicholson WT; Sprung J; Jankowski CJ
    Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myths and facts in neuromuscular pharmacology. New developments in reversing neuromuscular blockade.
    Fink H; Hollmann MW
    Minerva Anestesiol; 2012 Apr; 78(4):473-82. PubMed ID: 22454044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of Pipecuronium-Induced Moderate Neuromuscular Block with Sugammadex in the Presence of a Sevoflurane Anesthetic: A Randomized Trial.
    Tassonyi E; Pongrácz A; Nemes R; Asztalos L; Lengyel S; Fülesdi B
    Anesth Analg; 2015 Aug; 121(2):373-80. PubMed ID: 25923435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia.
    Rex C; Wagner S; Spies C; Scholz J; Rietbergen H; Heeringa M; Wulf H
    Anesthesiology; 2009 Jul; 111(1):30-5. PubMed ID: 19512873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on neuromuscular pharmacology.
    Naguib M; Brull SJ
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):483-90. PubMed ID: 19384229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.